Saturday, October 20, 2012
Grand Ballroom A/B (Hilton Riverside)
Ruthie R. Su, MD1, Paul A. Merguerian, MD, FAAP
2, Josephine Hidalgo-Tamola
3, Richard W. Grady
1, Thomas S. Lendvay
1 and Margarett Shnorhavorian
1, (1)Urology, Seattle Children's Hospital, Seattle, WA, (2)Division of Pediatric Urology, Seattle Children's Hospital, Seattle, WA, (3)Group Health Medical Center, Seattle, WA
Purpose: In 1996, a short-term
study at our institution showed patients treated with early valve ablation had
better bladder outcomes than those treated with urinary diversion. In
the same cohort, we examined whether these bladder outcomes endure with long-term
follow-up. Methods: This is a retrospective cohort study of patients
who underwent valve ablation (PVA, n=19) or urinary diversion (UD, n=6) during the
first year of life from 1986 to 1995. Pre-operative renal and bladder characteristics
were not significantly different. Clinical bladder outcomes measured were continence
at most recent follow-up, age at toilet training, age at nocturnal control, rate
of nocturnal enuresis and febrile UTIs, and resolution of hydronephrosis. Urodynamic
data during follow-up were reviewed for patterns of voiding dysfunction
classified as hypertonic, hyperreflexic, or myogenic failure. Renal outcomes
were defined as end stage renal disease (ESRD) (GFR < 15 mL/min per 1.73 m2).
To normalize the comparison groups, a subset analysis of bladder outcomes
amongst patients with ESRD was conducted. Results: Long-term follow-up a
median of 13 years (range 5-21 years) was available for 81% (25/31) of the
original valve cohort of which 74% (14/19) of PVA patients and 100% (6/6) of UD
patients had follow-up since 1996. PVA patients had significantly higher rates
of continence, underwent toilet training, and gained nocturnal urinary control
at an earlier age compared to UD patients (Table 1). At the time of follow-up,
5 of 19 (23%) PVA patients and 6 of 6 (100%) UD patients had developed ESRD (p<0.05).
A subset analysis of these patients with ESRD revealed more PVA patients were
continent (4/5, 80% versus 2/6, 33% of UD patients) and had resolution of hydronephrosis
(5/5, 100% versus 2/6, 33% of UD patients). Nocturnal enuresis and febrile UTIS
were less frequent in the PVA group (0/5, 0% and 0/5, 0% versus 3/6, 50% and
2/6, 33% of UD patients, respectively). Urodynamic evaluation was performed for
21 of 25 patients; on follow-up, 3 UD patients and 0 PVA patients demonstrated
late myogenic failure. Conclusions: PUV patients treated with early
valve ablation before the age of 1 year have clinically durable, improved
bladder outcomes compared to patients treated with urinary diversion even if
they develop end stage renal disease. Long term follow-up is imperative in this
population of patients to monitor for delayed bladder and renal dysfunction.
Table 1. Summary of bladder function at followup
| Ablation | Diversion |
Continence* | 16/18 (86%) | 2/6 (33%) |
Age at toilet training* | 5 years | 9 years |
Age at nocturnal control* | 6 years | 12 years |
Nocturnal Enuresis | 3/17 (18%) | 3/6 (50%) |
Recurrent UTIs* | 2/19 (11%) | 4/6 (66%) |
Bladder Augmentation | 1/19 (5%) | 2/6 (33%) |
*p<0.05